Diferencia entre revisiones de «Bromocriptine»
(Add dynamic SMW Indications by Condition table (auto-populated from disease pages via MedicationDose template)) |
(Switch SMW query from broadtable to table format for better layout with TOC) |
||
| (No se muestra una edición intermedia del mismo usuario) | |||
| Línea 106: | Línea 106: | ||
|?Has Route=Route | |?Has Route=Route | ||
|?Has Population=Population | |?Has Population=Population | ||
|format= | |format=table | ||
|headers=plain | |headers=plain | ||
| | |mainlabel=- | ||
|sort=Has Indication | |sort=Has Indication | ||
|limit=50 | |limit=50 | ||
Revisión actual - 21:57 20 mar 2026
Administration
- Type: Dopamine agonist
- Dosage Forms: capsule, tablet
- Dosage Strengths: capsule: 5mg; tablet: 0.8, 2.5mg
- Routes of Administration: PO
- Common Trade Names: Parlodel, Cycloset
Adult Dosing
- Acromegaly
- 20-30 mg PO QD
- Start: 1.25-2.5 mg PO qhs x3 days
- Increase by 1.25-2.5 mg per day q 3-7 days
- Max: 100 mg per day
- Give with food and taper dose to D/C
- Start: 1.25-2.5 mg PO qhs x3 days
- 20-30 mg PO QD
- Hyperprolactinemia
- 2.5-15 mg PO QD
- Start: 1.5-2.5 mg PO QD
- Increase by 1.25-2.5 mg per day q 2-7 days
- Give with food and taper dose to D/C
- Start: 1.5-2.5 mg PO QD
- 2.5-15 mg PO QD
- Parkinson's disease
- 10-30 mg PO tid
- Max: 100 mg/day
- Give with food and taper dose to D/C
- 10-30 mg PO tid
- Neuroleptic malignant syndrome
- 5-10 mg PO tid-QID
- Start: 2.5 mg PO tid-QID
- Increase dose as tolerated
- Max: 20 mg PO QID
- Continue x7-10 days, then taper dose over 3 days to D/C
- Start: 2.5 mg PO tid-QID
- 5-10 mg PO tid-QID
Pediatric Dosing
- Adenoma, prolactin-secreting
- 11-15 yo
- 2.5-10 mg PO QD
- Start: 1.25-2.5 mg PO QD
- Give with food and taper dose to D/C
- 2.5-10 mg PO QD
- 16+ yo
- 2.5-15 mg PO QD
- Start: 1.25-2.5 mg PO QD
- Give with food and taper dose to D/C
- 2.5-15 mg PO QD
- 11-15 yo
Special Populations
- Pregnancy Rating: B; No known risk of fetal harm based on human data. Monitor hyperprolactinemic pts closely for potential prolactin-secreting tumor enlargement.
- Lactation risk: L5; Contraindicated in postpartum lactation
Renal Dosing
- Adult: Not defined. Caution advised.
- Pediatric: Not defined. Caution advised.
Hepatic Dosing
- Adult: Not defined. Caution advised.
- Pediatric: Not defined. Caution advised.
Contraindications
- Allergy to class/drug
- Hypersensitivity to ergot derivatives
- Hypertension, uncontrolled
- Breastfeeding
- Avoid abrupt withdrawal
Adverse Reactions
Serious
- Seizure
- Stroke
- Hallucinations
- Syncope
- Hypotension
- Arrhythmia, MI
- Pericardial effusion, constrictive pericarditis
- Pleural effusion, pulmonary fibrosis
- Hypertension
- Raynaud phenomenon
- Retroperitoneal fibrosis
- GI bleeding
- Neuroleptic malignant syndrome-like symptoms if abrupt discontinuation
Common
- Nausea/vomiting, diarrhea, constipation, dyspepsia, anorexia, abdominal pain
- Headache, dizziness, fatigue
- Nasal congestion
- Orthostatic hypotension, orthostatic
- Involuntary movements, ataxia, visual disturbances
- Compulsive behaviors
- Digital vasospasm
- ALT, AST, alk phos elevation
Pharmacology
- Half-life: Biphasic 4-4.5 hr and 15 hr
- Metabolism: Liver; CYP450: 3A4 substrate
- Excretion: Bile 95%, urine 2.5-5.5%
Mechanism of Action
- Stimulates dopamine receptors
- Inhibits anterior pituitary prolactin secretion
Comments
Indications by Condition
The following table is automatically generated from disease/condition pages across WikEM.